Network medicine

[1]  P. Bork,et al.  Linear Motif Atlas for Phosphorylation-Dependent Signaling , 2008, Science Signaling.

[2]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[3]  Allegra Via,et al.  Phospho.ELM: a database of phosphorylation sites—update 2008 , 2007, Nucleic Acids Res..

[4]  F. White,et al.  Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach , 2007, Cell cycle.

[5]  K. Gunsalus,et al.  Network modeling links breast cancer susceptibility and centrosome dysfunction. , 2007, Nature genetics.

[6]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[7]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[8]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[9]  M. Mann,et al.  Is Proteomics the New Genomics? , 2007, Cell.

[10]  Douglas A. Lauffenburger,et al.  Common effector processing mediates cell-specific responses to stimuli , 2007, Nature.

[11]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[12]  P. Bork,et al.  Systematic Discovery of In Vivo Phosphorylation Networks , 2007, Cell.

[13]  C. Bakal,et al.  Quantitative Morphological Signatures Define Local Signaling Networks Regulating Cell Morphology , 2007, Science.

[14]  Eric S. Lander,et al.  Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.

[15]  W. Lim,et al.  Rewiring cellular morphology pathways with synthetic guanine nucleotide exchange factors , 2007, Nature.

[16]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[17]  D. Lauffenburger,et al.  Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks , 2007, Proceedings of the National Academy of Sciences.

[18]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[19]  N. Shah,et al.  Projecting future drug expenditures--2007. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[20]  Joseph A DiMasi,et al.  Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Forest M. White,et al.  Modeling HER2 Effects on Cell Behavior from Mass Spectrometry Phosphotyrosine Data , 2006, PLoS Comput. Biol..

[22]  Christian von Mering,et al.  STRING 7—recent developments in the integration and prediction of protein interactions , 2006, Nucleic Acids Res..

[23]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[24]  Ricardo Paxson,et al.  Model-based design approaches in drug discovery: A parallel to traditional engineering approaches , 2006, IBM J. Res. Dev..

[25]  Michael B. Yaffe,et al.  Data-driven modelling of signal-transduction networks , 2006, Nature Reviews Molecular Cell Biology.

[26]  Sampsa Hautaniemi,et al.  Effects of HER2 overexpression on cell signaling networks governing proliferation and migration , 2006, Molecular systems biology.

[27]  Alastair J J Wood,et al.  A proposal for radical changes in the drug-approval process. , 2006, The New England journal of medicine.

[28]  T. Pawson,et al.  Reading protein modifications with interaction domains , 2006, Nature Reviews Molecular Cell Biology.

[29]  J. Reichert.  Trends in US approvals: new biopharmaceuticals and vaccines , 2006, Trends in Biotechnology.

[30]  P. Bork,et al.  Proteome survey reveals modularity of the yeast cell machinery , 2006, Nature.

[31]  Sean R. Collins,et al.  Global landscape of protein complexes in the yeast Saccharomyces cerevisiae , 2006, Nature.

[32]  N. Powe,et al.  Are development times for pharmaceuticals increasing or decreasing? , 2006, Health affairs.

[33]  Henry G. Grabowski,et al.  The quantity and quality of worldwide new drug introductions, 1982-2003. , 2006, Health affairs.

[34]  K. Hunter,et al.  Mapping normal and cancer cell signalling networks: towards single-cell proteomics , 2006 .

[35]  D. Lauffenburger,et al.  A Systems Model of Signaling Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis , 2005, Science.

[36]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[37]  D. Lauffenburger,et al.  A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates , 2005, Nature Methods.

[38]  Tony Pawson,et al.  Synthetic modular systems – reverse engineering of signal transduction , 2005, FEBS letters.

[39]  Natasa Przulj,et al.  High-Throughput Mapping of a Dynamic Signaling Network in Mammalian Cells , 2005, Science.

[40]  M. Mann,et al.  Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics , 2004, Nature Biotechnology.

[41]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[42]  Tony Pawson,et al.  Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Janice M. Reichert,et al.  A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.

[44]  E. Triphosphat,et al.  FEBS Letters , 1987, FEBS Letters.

[45]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.